CAR-T TSA Screening Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Are you currently facing long development cycles, difficulty in identifying optimal CAR-T targets, or challenges in achieving robust and safe CAR-T therapies? Our CAR-T tumor-specific antigen (TSA) screening service helps you accelerate the discovery and validation of highly specific and immunogenic targets, enhancing the safety and efficacy of your CAR-T therapeutics, through advanced next-generation sequencing, sophisticated bioinformatics, and high-throughput functional validation platforms.

Introduction

Chimeric Antigen Receptor (CAR)-T cell therapy offers profound hope for cancer patients. However, its full potential, especially in solid tumors, is hindered by the challenge of identifying truly TSAs. Conventional methods often miss critical targets or lead to off-tumor toxicity. Creative Biolabs leverages advanced RNA-seq-based exhaustive peptide detection to uncover novel, highly specific neoantigens and tumor-associated antigens.

Fig.1 The rapid screening process of tumor-specific antigens utilized in engineered T-cell therapies. (OA Literature) Fig.1 A rapid screening process for tumor-specific antigens used in engineered T-cell therapy.¹

CAR-T TSA Screening Service at Creative Biolabs

Creative Biolabs' CAR-T TSA screening service is meticulously designed to provide you with a clear path to effective CAR-T therapy development. We deliver actionable insights and validated targets that minimize off-target toxicities and overcome tumor heterogeneity, accelerating your preclinical development. Our solutions include the identification of novel, highly specific, and immunogenic tumor antigens, ensuring your CAR-T constructs are precisely directed.

Creative Biolabs offers a comprehensive RNA-seq-driven neoantigen discovery and CAR-T development service. Our solutions include RNA-seq data generation, bioinformatic neoantigen prediction, custom peptide synthesis, MHC binding assays, and complete CAR-T cell design and validation. By integrating these capabilities, we enable the rapid identification of highly specific tumor antigens and the development of safer, more effective CAR-T therapies.

What We Can Offer

Next-Generation Sequencing	Bioinformatics & Computational
Illumina: high-throughput RNA-seq, detects mutations, fusions, and expression changes. Cell platforms: resolve tumor heterogeneity; profile antigen expression in cell subsets.	HLA typing software: Predict patient-specific HLA genotypes. MHC binding algorithms: Predict peptide–MHC binding affinity. Differential expression tools: Identify tumor-specific/highly expressed genes.
Proteomics Platforms	Functional Screening Platforms
Mass Spectrometry-based Immunopeptidomics: Identify and quantify MHC-presented peptides for antigen validation. High-resolution mass spectrometers: Enable deep, accurate proteome and immunopeptidome profiling.	Flow cytometry & cell sorting: High-throughput analysis of CAR-T activation, cytokines, and target lysis High-throughput imaging: Real-time, label-free monitoring of cytotoxicity and proliferation Multiplex cytokine platforms: Quantify multiple cytokines from activated CAR-T cells.

Service Process

The workflow of CAR-T TSA screening service. (Creative Biolabs Original)

Key Advantages

Precision Target Discovery: We dive deep, using advanced RNA-seq and sophisticated bioinformatics to find those truly TSAs and neoantigens. This means your CAR-T cells will only attack the bad guys, minimizing harmful off-target effects.
Comprehensive Validation: Beyond just finding targets, we put them through rigorous functional tests. We're talking in vitro assays that confirm your chosen antigens truly activate CAR-T cells and lead to effective tumor killing, while staying safe for normal cells.
Cell Resolution: Tumors are tricky, often heterogeneous. Our cell analysis ensures we identify antigens present even on rare, resilient tumor cell populations, helping you build CAR-T therapies that can truly overcome tumor escape.

FAQs

Q1: How does your service address tumor heterogeneity in antigen identification?

A1: Our service incorporates cell resolution antigen analysis, allowing us to identify antigens expressed by specific tumor cell subpopulations. This advanced approach ensures that we don't miss targets on rare but therapeutically critical cells, helping you design CAR-T cells that can effectively counteract tumor adaptation and relapse.

Q2: How do you ensure the identified antigens are truly tumor-specific and not expressed on healthy tissues?

A2: Our rigorous process involves extensive comparative analysis between tumor and matched normal samples, combined with advanced in silico filtering against comprehensive databases of normal tissue expression. Furthermore, our functional validation includes specific off-target toxicity assessments using panels of normal human cell lines, providing a robust multi-layered approach to confirm tumor specificity.

Why Choose Us?

Creative Biolabs stands at the forefront of CAR-T antigen discovery, distinguished by our deep expertise, cutting-edge technology, and unwavering commitment to your project's success. With over two decades of experience, we consistently deliver precise and actionable results that accelerate your therapeutic development.

Customer Reviews

"Creative Biolabs facilitated the discovery of novel targets in a highly heterogeneous sarcoma model. Their cell resolution analysis was particularly instrumental in uncovering subpopulation-specific antigens that our standard bulk sequencing methods missed. This level of detail is critical for developing CAR-T therapies that can combat tumor escape. Their data clarity and thoroughness were exceptional, allowing us to pursue targets with high confidence." Prof. L***a K.

"The rapid and reliable antigen validation from Creative Biolabs' service streamlined our preclinical pipeline. Their in silico predictions coupled with robust functional assays provided high-confidence targets, allowing us to proceed with CAR-T construct engineering much faster than anticipated. The comprehensive reports allowed for quick decision-making and saved significant research time and resources." J***e M.

How to Contact Us

Creative Biolabs is your dedicated partner in advancing CAR-T therapy development. Our CAR-T TSA screening service provides the precision and comprehensive data needed to drive your projects forward with confidence. We are committed to empowering your research with cutting-edge science and unparalleled support.

Reference

Li, Jiangping et al. "The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells." Molecular Cancer vol. 22,1 141. 30 Aug. 2023, https://doi.org/10.1186/s12943-023-01844-5. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.